User profiles for E. Small

Eric Evan Small

- Verified email at colorado.edu - Cited by 15754

Eric M. Small, Ph.D.

- Verified email at urmc.rochester.edu - Cited by 7814

Pervasive roles of microRNAs in cardiovascular biology

EM Small, EN Olson - Nature, 2011 - nature.com
… cell) 37,42 , the regulation of heart development may depend on either a relatively discrete
set of miRNAs or the combinatorial function of a larger array of miRNAs expressed at a low

MicroRNAs add a new dimension to cardiovascular disease

EM Small, RJA Frost, EN Olson - Circulation, 2010 - Am Heart Assoc
… Identification and validation of miRNA targets remain a major hurdle in the study of miRNA
function because many putative targets display little or no detectable regulation when tested …

State of the art in large‐scale soil moisture monitoring

…, KM Larson, EG Njoku, EE Small… - Soil Science Society …, 2013 - Wiley Online Library
Soil moisture is an essential climate variable influencing land–atmosphere interactions, an
essential hydrologic variable impacting rainfall–runoff processes, an essential ecological …

[HTML][HTML] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

…, M Kohli, MC Benson, EJ Small… - … England Journal of …, 2004 - Mass Medical Soc
Background Mitoxantrone-based chemotherapy palliates pain without extending survival in
men with progressive androgen-independent prostate cancer. We compared docetaxel plus …

[HTML][HTML] Sipuleucel-T immunotherapy for castration-resistant prostate cancer

…, ND Shore, ER Berger, EJ Small… - … England Journal of …, 2010 - Mass Medical Soc
Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown
evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant …

[HTML][HTML] Abiraterone in metastatic prostate cancer without previous chemotherapy

…, PFA Mulders, E Basch, EJ Small… - … England Journal of …, 2013 - Mass Medical Soc
Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We …

[HTML][HTML] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate …

…, E Basch, WK Kelly, WD Figg, EJ Small… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
… the formation of the Prostate Cancer Clinical Trials Working Group (PCWG2), a collective
of international investigators who developed this report through meetings and electronic

Convergence across biomes to a common rain-use efficiency

…, J Harte, GW Koch, S Schwinning, EE Small… - Nature, 2004 - nature.com
Water availability limits plant growth and production in almost all terrestrial ecosystems 1 , 2
, 3 , 4 , 5 . However, biomes differ substantially in sensitivity of aboveground net primary …

[PDF][PDF] Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate …

EJ Small, PF Schellhammer, CS Higano, CH Redfern… - J clin Oncol, 2006 - academia.edu
… Data from a small phase II study of sipuleucel-T demonstrated a trend in delaying TTP
correlating with T-cell immune response to PAP.Because of the confounding nature of …

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) …

…, K Miller, CJ Logothetis, ND Shore, EJ Small… - The Lancet …, 2015 - thelancet.com
… the setting of low disease burden (eg, few metastases, low serum … First, there is probably a
small, undefined subset of patients … Third, given the small number of events and the advanced …